Publication details
Secukinumab u pacientů se středně těžkou a těžkou formou ložiskové psoriázy – dlouhodobá účinnost prokázána
| Title in English | Secukinumab in moderate to severe plaque psoriasis patients – sustained high efficacy proved |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| Keywords | psoriasis – PASI – interleukin 17 - secukinumab |
| Description | Psoriasis is a chronic inflammatory systemic disease. Severe psoriasis considerably reduces the quality of patients‘ lives, is often associated with inflammatory systemic diseases and may shorten life expectancy. Therefore, the patients need long-term effective and safe treatment. Biological therapy, which targets the main inflammatory cytokines playing the crucial role in psoriasis developement, offers this possibility. Secukinumab, according to recently published clinical study results, demonstrates considerable and long-term effectivity during sustained administration. |